MedTrace Logo

Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML

NCT05262465 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2022-03-02

No results posted yet for this study

Summary

Patients enrolled from each center according to confirmed criteria specified in cooperative scheme are recieved induction and consolidation chemotherapy with microtransplantation . Observe the remission rate and 2-year disease-free survival (DFS) and overall survival(OS) rate.

Conditions

  • Adult Acute Myeloid Leukemia

Interventions

BIOLOGICAL

microtransplantation, HLA-mismatched donor peripheral stem cell infusion

HLA-mismatched donor peripheral stem cell infusion

DRUG

Azacitidine

azacytidine 50-75mg/m2

DRUG

Venetoclax

Venetoclax 100-300mg/d ×3d，400mg 4-28d

Sponsors & Collaborators

  • guomei

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2023-07-01
Completion
2025-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05262465 on ClinicalTrials.gov